La Jolla Pharmaceutical Company (LJPC) 2019年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Kx ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2019ORo TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For th

2、e transition period from toCommission file number:1-36282LA JOLLA PHARMACEUTICAL COMPANY(Exact name of registrant as specified in its charter)California 33-0361285(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)4550 Towne Centre Court,San Diego,CA 921

3、21(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(858)207-4264 Securities registered pursuant to Section 12(b)of the Act:Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock,par value$0.0001 per share LJPC The

4、 Nasdaq Capital Market Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No xIndicate by check mark if the registrant is not required to file reports pursuant to Se

5、ction 13 or 15(d)of the Securities Act.Yes o No xIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 duringthe preceding 12 months(or for such shorter period that the registrant was required to file s

6、uch reports),and(2)has been subject to such filing requirementsfor the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the prece